Company* |
Funding Institution | Amount (M) | Type |
Details (Date) |
Aastrom |
National Institutes of Health |
$0.79 |
Phase II SBIR grant |
To support development of the Aastrom Replicell System for large-scale manufacturing of cell-based products (10/18) |
Affectis |
German Ministry of Research and Education and the state of Bavaria |
€2.2 (US$2.6) | Grants |
The minstry is providing €1.7M for development of a depression drug that targets a specific ion channel; a Bavaria program is providing €0.5M for discovery of genes involved in depression and anxiety (10/18) |
AlphaVax Inc.* |
National Institute of Allergy and Infectious Diseases |
$3.3 |
Grant |
The funding will be used for preclinical development of a vaccine for smallpox (10/19) |
Argos |
Ontario Cancer Research Network |
$0.57 |
Grant |
McMaster University got the grant to fund a clinical trial of Argos' RNA-loaded dendritic cell vaccine technology in chronic lymphocytic leukemia (11/8) |
Ark Therapeutics |
Employment and Economic Development Center of Finland |
€2.19 (US$2.5) |
Grant |
Funding will support the company's investment in GMP manufacturing facility in Kuopio, Finland (11/3) |
Bolder |
National Institute of General Medical Sciences |
$0.122 |
Phase I SBIR grant |
Bolder will optimize the pharmacological properties of an enzyme, butyrylcholinesterase, which is capable of inactivating toxic nerve agents (10/10) |
Cellzome Inc.* |
German Ministry of Research and Education |
€2.2 (US$2.6) |
Grants |
Cellzome and Santhera's Graffinity will use funding to support discovery of treatments for immune system disorders (10/12) |
Cerus Corp. |
National Institute of Allergy and Infectious Diseases |
$2.8 |
Contract |
Cerus is getting $2.8M as part of a consortium to develop a prophylactic vaccine against the bacterium that causes tularemia; the total contract is $23M (10/5) |
Chiron Corp. |
U.S. Department of Health and Human Services |
$62.5 |
Contract |
Chiron won a contract to supply the U.S. government with pre-pandemic influenza vaccine for a stockpile to protect against the H5N1 avian influenza virus strain (10/27) |
CollaGenex |
National Institutes of Health |
$0.962 |
Grant |
The two-year grant will support research into the anti-inflammatory effects of incyclinide (Col-3) a compound currently in Phase II trials for treating acne (11/9) |
CombiMatrix |
U.S. Air Force |
$0.338 |
Contract |
One-year contract to develop and produce microarrays to detect pathogens that cause upper respiratory infections and pathogens that infect wounds (9/28) |
Cyprotex plc |
Department of Trade & Industry (UK) |
ND |
Grant |
The grant will be used to extend Cyprotex's predictive technologies used in the invention of new drugs (10/26) |
Deltagen Inc. |
National Institutes of Health |
ND |
Contract award |
Deltagen will provide knockout mice to NIH and its partners (10/5) |
Edison |
Friedreich's Ataxia Research Alliance |
$3 |
Grant |
The grant will be used to advance development of EPI- A0001 for treating Friedreich's ataxia (11/8) |
Edison |
Friedreich's Ataxia Research Alliance |
$0.3 |
Grant |
Funding will support work at Edison in Friedreich's ataxia (10/25) |
Edison |
Muscular Dystrophy Foundation |
ND |
Funding support |
Funding will support work at Edison in Friedreich's ataxia (10/20) |
Epitome |
National Science Foundation |
$0.5 |
Phase II SBIR grant |
Epitome will develop an antibody array that will integrate the measurement of phosphoproteins from three cell-signaling pathways into a single assay sys- tem (10/17) |
FASgen Inc.* |
National Institutes of Health |
$2.1 |
SBIR grant |
Funds will support completion of preclinical work on small-molecule drugs for obesity and related metabolic disorders (10/17) |
Galenea Corp.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
For further development of the company's siRNA product G00101 against multiple influenza strains, including avian flu (11/17) |
Genencor |
U.S. Department of Defense |
$2 |
Contract |
Genencor will work with the U.S. Army Edgewood Chemical and Biological Center to develop an enzyme-based decontamination solution targeting chemical and biological warfare agents (10/31) |
GenPat77* |
German Ministry of Research and Education |
ND |
BioChancePLUS program grant |
The grant will support development of its immunomodulator program in inflammatory bowel disease (10/11) |
GenVec Inc. |
National Institute of Allergy and Infectious Diseases |
$9.9 |
Subcontract award from SAIC-rederick contract |
GenVec got increased funding for its HIV vaccine development work with the Vaccine Research Center of the NIAID (10/5) |
Human Genome |
U.S. Department of Health and Human Services |
$1.8 |
Contract award |
HGS first will supply the ABthrax anthrax monoclonal antibody for preclinical testing; that could lead to an order within a year for up to 100,000 doses for the national stockpile; $1.8M was awarded for the first stage (10/3) |
Icoria Inc. |
National Institute on Alcohol Abuse and Alcoholism |
$0.8 |
Phase II SBIR grant |
Icoria will apply metabolomics and gene expression analysis in the study of alcohol-related diseases, including liver and brain injury (10/20) |
LAB |
National Technology Agency of Finland |
€1.55(US$1.8) |
Funding support |
LAB's subsidiary in Finland, LAB Pharma, got funding to support product development; the money includes grants and loans (10/20) |
Lexicon |
National Institutes of Health |
$4.9 |
Contract |
Three-year deal under which Lexicon will provide knockout mouse lines and related data for use in NIH's Knockout Mouse Project (10/5) |
LigoCyte |
National Institutes of Health |
$4.6 |
Challenge grant |
The grant will support preclinical advancement of an intranasal vaccine against anthrax (10/3) |
Maxygen Inc. |
National Institutes of Health |
$12 |
Grants |
One grant will support use of the MolecularBreeding directed evolution platform to generate antigens capable of inducing antibody responses to multiple HIV strains; a Phase I SBIR grant also supports HIV research (10/20) |
Maxygen Inc. |
U.S. Department of Defense |
$2.4 |
Contract |
The funding supports development of a high- throughput vaccine screening platform (10/20) |
Metabolon |
Centers for Disease Control and Prevention |
ND |
Contract |
Metabolon will analyze blood samples to identify disease biomarkers for multiple sclerosis (10/26) |
MicroIslet Inc. |
National Institutes of Health |
$1.7 |
Phase II SBIR grant |
The three-year award will be used to further develop its islet cell transplantation technology for treating diabetes (10/5) |
MNLpharma |
Welsh Development Agency |
£0.709 (US$1.2) |
SMARTCymru program grant |
Grant will go toward development of the immune modulator MNLP 462a as a cancer agent (11/21) |
Neotropix Inc.* |
Pennsylvania Dept. of Community and Economic Development |
$0.05 |
Opportunity grant |
The grant will help support research and development at Neotropix (9/28) |
Optimer |
National Institute of Allergy and Infectious Diseases |
$1.19 |
Phase II SBIR grant |
Grant supports development of semi-synthetic macrolides and ketolides as antimicrobial agents (10/17) |
Optimer |
National Institute of Allergy and Infectious Diseases |
$0.73 |
SBIR-Advanced Technology grant |
The grant will help fund development of OPT-80, which is in a Phase II trial for Clostridium difficile-associated diarrhea (10/17) |
Peregrine |
U.S. Department of Defense |
$0.58 |
Grant |
The University of Texas Southwestern Medical Center got fund- ing to study vascular targeting antibodies with chemotherapy for treating prostate cancer (11/3) |
Phylogica Ltd. |
Australian government |
A$2.27 |
AusIndustry Commercial Ready grant |
Grant will support development of Phylomer drug candidates for rheumatoid arthritis (10/24) |
Point |
Food and Drug Administration |
$0.6 |
Orphan Products Development grant |
The two-year grant will fund the Phase II trial of talabostat in combination with rituximab in advanced chronic lymphocytic leukemia (10/11) |
Provid |
National Cancer Institute |
$0.75 |
Phase II SBIR contract |
Provid will use its hypothesis-driven drug discovery chemistry in a two- ear collaboration on oncology targets (9/29) |
Reata |
National Institutes of Health |
ND |
Phase I SBIR grant |
The grant will support development of small-molecule drugs for treating amyotrophic lateral sclerosis (11/3) |
Repligen |
Stanley Medical Research Institute |
$1 |
Funding support |
Repligen will get the money under an expanded agreement between the parties for a Phase II trial of uridine in bipolar depression (10/21) |
Saneron CCEL |
National Institutes of Health and the state of Florida |
$0.26 |
Phase I STTR grant and Florida High Tech Corridor matching grant |
The grant will support a study to evaluate the effects of umbilical cord blood transplantation following myocardial infarction in a large animal model (10/11) |
Sangamo |
Cystic Fibrosis Foundation |
ND |
Research funding |
Sangamo gets two years of funding to generate cell lines for cystic fibrosis research using its zinc finger DNA-binding protein technology (9/29) |
SeraCare |
National Cancer Institute |
ND |
Contract expansion |
SeraCare will provide laboratory support to the NCI for the processing and storage of specimens of people at high risk for cancer; it also will act as a repository for the specimens (10/6) |
SIGA |
U.S. Army Medical Research and Materiel Command |
$3.2 |
Contract |
One-year contract to use its computational approach to develop countermeasures against smallpox and adenovirus (9/27) |
Solbec |
Western Australia Department of Industry and Resources |
A$0.023 (US$0.017) |
Grant |
The grant will be used to help secure funding for further trials of the company's cancer drug Coramsine (11/18) |
Starpharma |
National Institute of Allergy and Infectious Diseases |
$20.3 |
Development funding |
The funding will support development of the vaginal microbicide VivaGel through to the start of large-scale efficacy trials (10/3) |
Targeted |
National Institute of Allergy and Infectious Diseases |
$18 |
Subcontract award |
Targeted Genetics could receive up to $18M of a $21.75M contract over three years for further development of adeno-associated virus-based vaccines against HIV; two research hospitals also are participating in the award (11/28) |
To-BBB BV* |
Sanfilippo Syndrome Medical Research Center |
$0.1 |
Grant |
The grant supports a preclinical program on targeting sulphamidase to the brain for treating neurological disorders (10/20) |
U.S Genomics |
U.S. Department of Homeland Security |
$16.8 |
Phase II Advanced Research Project Agency contract |
U.S. Genomics will complete prototype development of its system for detecting and identifying airborne pathogens using its DNA mapping technology (11/30) |
U.S. Genomics |
National Science Foundation |
$0.5 |
Phase II-B SBIR grant |
The grant will support development of a platform that uses the company's DNA analysis and genomic mapping technologies (10/5) |
VisiGen |
National Institutes of Health |
ND |
Phase I SBIR grant |
The grant will support development of a method for labeling DNA, RNA and proteins (9/26) |
VisiGen |
National Human Genome Research Institute |
$4.2 |
Genome grant |
Three-year grant will help accelerate development of VisiGen's sequencing technology (8/6)# |
Xanthus Life |
National Cancer Institute |
$2.3 |
Grant |
Xanthus gets up to $2.3M to develop its ParaMetabolic technology to improve the way cancer drugs are dosed (9/29) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
# Item occured before the time frame of this chart but was not included in previous chart. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.